在2025年中国博览会上,中华生物制药公司通过AI驱动的保险一体化,合作促进人们获得负担得起的创新药品。 MediTrust Health and Sino Biopharm partnered to boost access to affordable, innovative drugs via AI-driven insurance integration at the 2025 China Expo.

在2025年中国国际进口博览会上,MediTrust Health和Sino生物制药公司签署了一项推进药物保险一体化的战略协定,目的是改善获得创新、负担得起的药品的机会。 At the 2025 China International Import Expo, MediTrust Health and Sino Biopharm signed a strategic agreement to advance drug-insurance integration, aiming to improve access to innovative, affordable medicines. 这一伙伴关系将制药创新与商业健康保险相结合,利用AI和数据来简化诊断、治疗和支付。 The partnership combines pharmaceutical innovation with commercial health insurance, using AI and data to streamline diagnosis, treatment, and payment. 中国生物制药公司拥有120多种输油管药物和300亿元人民币的年收入,强调了保险在支持可持续研发方面的作用。 Sino Biopharm, with over 120 pipeline drugs and RMB 30 billion in annual revenue, highlighted insurance’s role in supporting sustainable R&D. 据报道,到2024年底,MediTrust Health将在160个城市提供3.93亿份保险,为患者节省了67亿元人民币的成本. MediTrust Health, serving 393 million policies across 160 cities by late 2024, reported RMB 6.7 billion in patient cost savings. 该倡议支持中国的“健康中国2030年”战略,创建了更高效、以病人为中心的医疗生态系统。 The initiative supports China’s “Healthy China 2030” strategy by creating a more efficient, patient-centered healthcare ecosystem.